About
Brendan Swain, PhD is the co-founder and Chief Scientific Officer of Shift Bioscience, a Cambridge biotech developing AI-enabled cell rejuvenation therapeutics for age-related disease. Shift states that he has led the company's scientific program since 2021 and pioneered an accurate single-cell aging clock. He earned a PhD in pharmacology from the University of Cambridge.
Areas of interest
longevitybiotechcell rejuvenationaging clockssingle-cell transcriptomicsmachine learning for biologygenerative AI for drug discoverygene target discoveryfibrosisregenerative medicine